204 related articles for article (PubMed ID: 21300150)
41. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
42. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Poirier D
Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.
Deluca D; Möller G; Rosinus A; Elger W; Hillisch A; Adamski J
Mol Cell Endocrinol; 2006 Mar; 248(1-2):218-24. PubMed ID: 16406285
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
45. Biological activity of pyrazole and imidazole-dehydroepiandrosterone derivatives on the activity of 17β-hydroxysteroid dehydrogenase.
Cabeza M; Posada A; Sánchez-Márquez A; Heuze Y; Moreno I; Soriano J; Garrido M; Cortés F; Bratoeff E
J Enzyme Inhib Med Chem; 2016; 31(1):53-62. PubMed ID: 25690043
[TBL] [Abstract][Full Text] [Related]
46. Interference of Paraben Compounds with Estrogen Metabolism by Inhibition of 17β-Hydroxysteroid Dehydrogenases.
Engeli RT; Rohrer SR; Vuorinen A; Herdlinger S; Kaserer T; Leugger S; Schuster D; Odermatt A
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28925944
[TBL] [Abstract][Full Text] [Related]
47. A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men.
Jakobsson J; Palonek E; Lorentzon M; Ohlsson C; Rane A; Ekström L
Pharmacogenomics J; 2007 Aug; 7(4):282-9. PubMed ID: 16983398
[TBL] [Abstract][Full Text] [Related]
48. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of solvent accessibility epitopes for different dehydrogenase inhibitors.
Ludwig C; Michiels PJ; Lodi A; Ride J; Bunce C; Günther UL
ChemMedChem; 2008 Sep; 3(9):1371-6. PubMed ID: 18576452
[TBL] [Abstract][Full Text] [Related]
50. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
[TBL] [Abstract][Full Text] [Related]
51. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
[TBL] [Abstract][Full Text] [Related]
52. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
53. Structure-based design and profiling of novel 17β-HSD14 inhibitors.
Braun F; Bertoletti N; Möller G; Adamski J; Frotscher M; Guragossian N; Madeira Gírio PA; Le Borgne M; Ettouati L; Falson P; Müller S; Vollmer G; Heine A; Klebe G; Marchais-Oberwinkler S
Eur J Med Chem; 2018 Jul; 155():61-76. PubMed ID: 29859505
[TBL] [Abstract][Full Text] [Related]
54. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
[TBL] [Abstract][Full Text] [Related]
55. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
56. Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors.
Kulkarni S; Singh Y; Biharee A; Bhatia N; Monga V; Thareja S
J Biomol Struct Dyn; 2023; 41(22):12668-12685. PubMed ID: 36744535
[TBL] [Abstract][Full Text] [Related]
57. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
[TBL] [Abstract][Full Text] [Related]
58. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
60. New Insights into Human 17β-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal Inhibitor.
Bertoletti N; Braun F; Lepage M; Möller G; Adamski J; Heine A; Klebe G; Marchais-Oberwinkler S
J Med Chem; 2016 Jul; 59(14):6961-7. PubMed ID: 27362750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
